Product category: Diagnostic agents / kits for tumour marker determination
Catalog Number: K41001-R10/R05 Package Size: K41001-R10: For 50-100 IHC Tests with frozen or FFPE tissues K41001-R05: For 25-50 IHC Tests with frozen or FFPE tissues Concentration: Ready to use Specificity: Cytokeratins 8 and 18 Species Reactivity: Human Storage: 4°C upon receiving. Do not freeze. Applications: Immunohistochemistry
The key component in this kit is horseradish peroxidase (HRP) polymer (polyHRP) labeled mouse anti-human cytokeratin 8/18 antibody. The product is developed based on Novodiax’s proprietary enzyme polymerization technology and Direct IHC technology (Patent Pending) and is optimized for IHC on frozen tissue. Its incubation time on frozen tissues is 3 minutes and on FFPE tissues 15 minutes. Monoclonal antibody Clone C94 reacts with human cytokeratin intermediate low molecular weight filament proteins of 52.5 kD and 45 kD, i.e., cytokeratins 8 and 18, respectively. Cytokeratins 8 and 18 are expressed in most simple and glandular epithelium, such as thyroid, female breast, gastrointestinal tract, and respiratory tract. In cancer tissues, whereas adenocarcinomas and most non-keratinizing squamous carcinomas express these proteins, keratinizing squamous carcinomas does not. Antibodies to CK8 and 18 may be utilized in the classification of tumors of epithelial origin.
Novodiax has developed a proprietary supersensitive enzymatic signal amplification detection system that meets the needs of immunohistochemistry laboratories through intelligent structural designs and optimal polymerization. We created a spectrum of related cutting edge polymer product lines and services based on this technology: • The revolutionary 10 minute Intraoperative IHC kits. • Q-StainTM PolyHRp-secondary antibodies and streptavidin products • ihcDirectTM PolyHRp-primary antibody conjugates are simple and fast. See our products and services. • Custom PolyHPR Conjugation Service accelerates your therapeutic antibody development and ELISA test kit development. • Companion diagnostic development partnering.